News from onclive.comFollowNews from onclive.comYour destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today.We’ve aggregated 810 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Your destination for news from onclive.com. See how onclive.com’s media bias impacts the breaking news stories of today. We’ve aggregated 810 of onclive.com’s headlines and news stories over the past 3 months. onclive.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. onclive.com’s aggregated factuality score is unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about onclive.comWhere is onclive.com located?onclive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top onclive.com NewsBreast Cancer · United StatesPI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer100% Center coverage: 1 sourcesThe FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA-mutated, hormone receptor (HR)-positive/HER2-negative breast cancer that recurred during or after adjuvant endocrine therapy. Support for the approval came from the multicenter randomized INAVO120 trial, which showed that the addition of inavolisib to palbociclib […]See the StoryUnited States · United StatesVerastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual MeetingPromising results: Verastem's LGSOC therapy shows 31% response rate, 12.9-month PFS. FDA submission planned for 2024, aiming to be first approved treatment for KRAS mutant LGSOC.See the StoryOsimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLCAdding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.See the StoryLatest News StoriesTopics Most Covered by onclive.comBreast CancerCancerMerckEuropean UnionFDABreast CancerCancerMerckSources Covering Similar Topicstargetedonc.comcancernetwork.comstocktitan.netPharmacy Timespipelinereviewtargetedonc.comcancernetwork.comstocktitan.netSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to onclive.comCalifornia, United StatesMarylandCancerBreast CancerUnited States